CSIR-URDIP has a vibrant scientific community consisting of Scientists, Intellectual Property Specialists, Technologists and Project Assistants. The scientific staff are the true strength of CSIR-URDIP. Scientists and Technologists are permanent employees while Project Assistants are hired for a fixed duration depending upon the needs of a particular project. We have an open work culture where talents are honed, achievements recognized, and every contribution is valued. Hierarchy matters very little when it comes to working relationships at CSIR-URDIP.

The Indian Army promises both professional and personal growth at every stage of the career. Opportunities to excel through various courses are abundant including opportunities to enhance your educational qualification by availing two years paid study leave. The inherent adventure and extra-curricular activities in the Army ensure an all round development essential in today's world. Art of War-Engineering-Medicine-Administration-Human Resource Development and Management; the army teaches you all.

Applications are invited for the following posts under Zilla Parishad Nashik.

Post : Pharmacist

No of Posts : 05
Qualification : Candidates with a degree or diploma in Pharmacy and registered pharmaceutical manufacturers under the Pharmacy Act 1948.
Salary : 16600/-

The Indian Army promises both professional and personal growth at every stage of the career. Opportunities to excel through various courses are abundant including opportunities to enhance your educational qualification by availing two years paid study leave. The inherent adventure and extra-curricular activities in the Army ensure an all round development essential in today's world. Art of War-Engineering-Medicine-Administration-Human Resource Development and Management; the army teaches you all.

AUROBINDO PHARMA LTD (APL) is a growing Indian multinational pharmaceutical manufacturing firm with turnover of over US$2.8 Billion revenues for 2018-19, with presence in more than 34 countries fronted presence with products exported to 155 nations. 

Biotech Consortium India Limited (BCIL) is a public limited company, promoted by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India and set up by All India Financial Institutions including IDBI, ICICI, IFCI, UTI and IFCI Venture Capital Funds Limited. BCIL was incorporated under the Companies Act 1956(Now Company Act, 2013) in 1990 with government in advisory role, development banks as major funding agency.

Amoli Organics Sites are CGMP and SHE compliant USFDA, ANVISA, EDQM, COFEPRIS- Cleared. Company’s Presence is in USA, EUROPE, JAPAN, RUSSIA, SOUTH EAST ASIA, MIDDLE EAST AND LATAM. Amoli has a successful track record in the pharmaceutical and allied industry. Making a beginning as a manufacturer of API"s and Intermediates.

Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support.

Post : Specialist - Quality Projects

ACCF (Assam Cancer Care Foundation) is a section 8 company and a joint initiative of the Government of Assam and the Tata Trusts, established to create a three-tier comprehensive model serving all sections of society. ACCF is coming up with digitally-enabled, modern cancer hospitals with state-of-the-art technology, which includes radiation equipment, in Tezpur and Barpeta, Assam. These hospitals have an occupancy of 135 beds in Barpeta, and 44 beds in Tezpur.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics.

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division, Stefan Oelrich, made the following statement  “Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus.

Eli Lilly and Company has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19 treatments.  Multiple neutralizing antibody therapies, administered via intravenous infusion, have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.

Eisai Co., Ltd announced that Eisai Korea Inc., Eisai’s subsidiary in South Korea, has launched the Parkinson’s disease treatment Equfina® (safinamide mesilate, “safinamide”). This is the first launch of Equfina in the Asian region excluding Japan.

India Inc. and especially the Healthcare industry which has been battling the demon of COVID-19 and its aftermath should consider this year’s budget a blessing. Quite rightly, the budget has focused on health and well-being, infrastructural reforms, development of human capital and minimum government and maximum governance. The very fact that the Government has put health as the first pillar shows that finally it is being considered as the prerequisite to ensure the economic well-being of the country.

Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs.

The CSIR-Institute of Microbial Technology (IMTECH) is a constituent R&D establishment of the Council of Scientific and Industrial Research (CSIR) devoted to research in the frontline areas of Microbial Biology and Biotechnology.

CSIR-IHBT is one of the 38 national laboratories of the Council of Scientific Industrial Research. It is located in the backdrop of snow-covered peaks of Dhauladhar mountain range at an elevation of 1300 m amsl. The Institute has a focus to develop technologies for boosting bioeconomy through sustainable utilization of Himalayan bioresources for societal, industrial and environmental benefits.

The Indian Institute of Technology Kanpur was established in the year 1960. The Parliament of India passed the ‘Institutes of Technology Act 1961’ declaring all the IITs as “Institutions of National Importance”. The Parliamentary Act has given absolute autonomy to the IITs. When the foundation stone of the IIT system was laid, it was perceived that taking help from the industrially advanced western countries might be lot more effective in achieving the status of a world class technical institute.

Regional Centre for Biotechnology (RCB), an Institution of national importance established by the Department of Biotechnology, Govt. of India, with regional and global partnerships synergizing with the programmes of UNESCO. The primary focus of RCB is to provide world class education, training and conduct innovative research at the interface of multiple disciplines to create high quality human resource in disciplinary and interdisciplinary areas of biotechnology in a globally competitive research milieu.